The Breast to Bone (B2B) Cohort Study to Prevent, Detect and Improve Treatment of Metastatic Disease: Baseline Assessment, Description and Progress

Nigel T. Brockton, Linda S. Cook, Anthony M. Magliocco, Carrie S. Shemanko, Hans J. Vogel, Momtafin Khan and Karen A. Kopciuk ()
Additional contact information
Nigel T. Brockton: American Institute for Cancer Research, Arlington, VA 22209, USA
Linda S. Cook: Department of Epidemiology, Colorado School of Public Health, University of Colorado, Aurora, CO 80045, USA
Anthony M. Magliocco: Protean Biodiagnostics, Orlando, FL 32827, USA
Carrie S. Shemanko: Department of Biological Sciences, Faculty of Science, University of Calgary, Calgary, AB T2N 1N4, Canada
Hans J. Vogel: Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB T2N 4N1, Canada
Momtafin Khan: Department of Cancer Epidemiology and Prevention Research, Cancer Care Alberta, Alberta Health Services, Arthur JE Child Comprehensive Cancer Centre, 7th Floor, Room YC071 414, 3395 Hospital Drive N.W., Calgary, AB T2N 5G2, Canada
Karen A. Kopciuk: Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB T2N 4N1, Canada

IJERPH, 2025, vol. 22, issue 2, 1-15

Abstract: Women diagnosed with early-stage breast cancer can develop metastatic disease following successful initial treatment, with bone being the most common site of metastases. The Breast to Bone (B2B) cohort study of early-stage breast cancer patients was established as a research platform to study the basic biology of breast cancer to bone metastasis and to identify the factors that could improve prevention, early detection and treatment for this debilitating and incurable disease. The B2B cohort includes 478 women diagnosed with incident primary breast cancer (stages I to III) who were recruited from Calgary, Alberta and surrounding areas between February 2010 and July 2015. Four projects have been conducted to date, utilizing data and samples from this cohort. These studies have found the following: (a) women with insufficient or deficient levels of vitamin D (25[OH]D) concentrations in pretreatment serum samples had larger tumors and higher breast cancer grades, (b) several metabolomic biomarkers and cytokines were associated with tumor characteristics and time to recurrence, (c) additional biomarkers were found to be predictive for the high risk of bone metastasis and (d) circulating progastrin (hPG80) was associated with multiple survival outcomes. These research studies and future ones will provide new evidence on bone metastasis etiology in women diagnosed with early-stage breast cancer, improve identification of those at high risk and contribute to personalized treatment and prevention options.

Keywords: breast cancer; cohort; bone metastases; progastrin (hPG 80 ); vitamin D; survival; treatment (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2025
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/22/2/242/pdf (application/pdf)
https://www.mdpi.com/1660-4601/22/2/242/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:22:y:2025:i:2:p:242-:d:1586787

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().